Research programme: genetically modified interferon-beta molecules - GBF

Drug Profile

Research programme: genetically modified interferon-beta molecules - GBF

Alternative Names: Soluferon

Latest Information Update: 29 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GBF
  • Developer Vakzine Projekt Management
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatitis C; Multiple sclerosis

Most Recent Events

  • 29 Jul 2016 Preclinical development for Multiple sclerosis is ongoing in Germany
  • 30 Nov 2005 Preclinical trials in Multiple sclerosis in Germany (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top